Raymond James Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.59B Sell
9,906,657
-503,502
-5% -$129M 0.69% 19
2026
Q2
$2.62B Buy
10,410,159
+805,810
+8% +$173M 0.71% 17
2026
Q1
$2.09B Buy
9,604,349
+206,615
+2% +$45.8M 0.64% 20
2025
Q4
$2.15B Sell
9,397,734
-159,967
-2% -$36.4M 0.67% 19
2025
Q3
$2.21B Buy
9,557,701
+220,221
+2% +$44.8M 0.71% 18
2025
Q2
$1.73B Buy
9,337,480
+2,753,312
+42% +$512M 0.6% 22
2025
Q1
$1.38B Sell
6,584,168
-117,866
-2% -$22.9M 0.52% 27
2024
Q4
$1.19B Buy
+6,702,034
New +$1.23B 0.44% 32

Other funds holding ABBV

Raymond James Financial's ABBV Position: Q3 2026 in Review

Raymond James Financial reduced its AbbVie (ABBV) stake by 4.8% in Q3 2026, selling an estimated $129M and leaving 9,906,657 shares worth $2.59B. The position accounts for 0.69% of the portfolio, ranked #19.

Raymond James Financial first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.62B in Q2 2026. 4,052 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Raymond James Financial held 9,906,657 shares of AbbVie worth $2.59B as of Q3 2026.
  • Raymond James Financial sold 503,502 AbbVie shares in Q3 2026, an estimated $129M.
  • AbbVie made up 0.69% of Raymond James Financial's portfolio in Q3 2026, its #19 holding.
  • Raymond James Financial first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's AbbVie position peaked at $2.62B in Q2 2026.
  • 4,052 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.